Prophylactic Dexamethasone on Pain Flare in Spine Metastasis Stereotactic Body Radiotherapy and Hypofractionated Radiotherapy
10.3971/j.issn.1000-8578.2021.21.0298
- VernacularTitle:地塞米松在椎体转移立体定向和大分割放疗中预防疼痛爆发的研究
- Author:
Runmei WANG
1
;
Hao YANG
;
Rong YU
;
Zhenfei WANG
;
Yu WU
;
Hong LI
;
Yue HU
Author Information
1. Department of Radiation Oncology, Inner Mongolia Cancer Hospital and Affiliated People's Hospital of Inner Mongolia Medical University, Hohhot 010020, China
- Publication Type:Research Article
- Keywords:
Dexamethasone;
Spine metastasis;
Stereotactic body radiation therapy;
Pain flare
- From:
Cancer Research on Prevention and Treatment
2021;48(12):1096-1100
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the incidence of pain flare (PF) in spine metastasis stereotactic body radiotherapy (SBRT) or hypofractionated radiotherapy (HF) and the prophylactical effect of dexamethasone. Methods Sixty-five patients were treated with spine metastasis SBRT and randomly divided into control group (SBRT or HF, n=32) and treatment group (SBRT or HF and 4.5 mg dexamethasone, n=33). The brief pain inventory (BPI) was used to score the pain before, during and after treatment. PF was recorded and compared between two groups. Results The incidence of PF was 24.6% in all patients (control group: 37.5%, treatment group: 12.1%, P=0.018). PF in both group occurred in d1-2, accounting for 62.5% in all PF (control group: 66.7%, treatment group: 50%, P=0.551). The incidences of PF in control group were 66.7% and 33.3% for three and ten fractions scheme, respectively (P=0.001). However, the incidences of PF in treatment group were 50% and 50% for three and ten fractions scheme, respectively (P=0.643). Conclusion Oral dexamethasone has an excellent efficacy in prevention and treatment of PF in spine metastasis SBRT or HF, with significantly decreased incidence of PF. A phase Ⅲ clinical trial is required to finalize the optimal dose and schedule.
